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Prostate cancer, unlike cancers of other sites, often has a very indolent natural history. Cytokines such as 
interleukin 10 (IL-10) may play an important role in prostate cancer through inflamination. Single nucleotide 
polymorphism (SNP) may regulate the biosynthesis, activations, and inactivation of genes and could influence 
the pathogenesis of disease initiation and progression. The aim of the present study is to assess the 
association of the two polymorphisms of Ll-10 (592C/A and 1080G-A) with risk of prostate cancer. One hundred 
fifty prostate cancer patients, one hundred fifty Benign Prostate Hyperplasia and equal number of age matched 
control groups were recruited from north Indian population for this case control study. The polymerase chain 
reaction (PCR) and restriction fragment length polymorphisms (RFLP) were utilized to amplify the gene of 
interest and identify the genotypes of IL-10 592 and IL-101080. Statistically non significant 1.74 and 1.67 folds 
of increased risk of prostate cancer was observed due to the gene-gene interactions of AC of IL-10-592 and GG 
of IL-10 1082 and AA of IL-10 -592 and  CC of IL-10 1082, respectively.  
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INTRODUCTION  
 
Prostate cancer is a common condition worldwide. 
Different geographical regions have varying incidence and 
mortality. Globally, prostate cancer is the sixth most 
common cancer, and the third most common cancer in 
men in developed countries. The risk of prostate cancer is 
increased by African-American ethnicity, increasing age, 
positive family history, and other factors such as diet. 
Nonetheless, the causes of prostate cancer are not well 
understood compared with other common cancers like lung 
and breast cancer (Kumar et al., 2004).  IL-10 is a 
pleiotropic cytokine with both anti-inflammatory and anti-
angiogenic properties. The anti-inflammatory properties of 
IL-10 are hypothesized to have pro-tumorigenic potential 
by enabling tumor cells to escape immune surveillance. 
Paradoxically, IL-10 also has anti-tumorigenic properties, 
since in both animal and in vitro models; IL-10 has been 
shown to reduce both tumor growth and angiogenesis 
(Huang et al., 1996; Stearns et al., 1997; Stearns and 
Wang, 1998; Stearns et al., 1999). The gene encoding IL-
10 is located on chromosome 1 (1q31-1q32), and many 
polymorphisms of the IL-10 gene promoter have been 
described. Examples of polymorphisms include -1082  A/ G  
 
 
 
 
(rs 1800896), -819 T/C (rs1800871) and -592 A/C 
(rs1800872) in the proximal region, which influence the 
transcription of IL-10 mRNA and the expression of IL- 10 in 
vitro (Kingo et al., 2005 ; Turner et al., 1997; Gibson et al., 
2001). IL-10-G1082A polymorphism is correlated with the 
expression of IL-10 and accordingly affects the 
susceptibility to some types of tumors, such as cervical 
cancer (Roh et al., 2002) and prostate cancer (McCarron et 
al., 2002). Although the expression of IL-10 gene might be 
associated with the susceptibility to oesophagal scoumous 
cell carcinoma (Nagata et al., 2002), the correlation of IL-
10 -1082 promoter polymorphism with the risk of prostate 
cancer in north Indian population has not been reported so 
far. Some workers have suggested that as much as 75% of 
inter-individual variation in IL-10 expression may be due to 
genetic variation, although others believe that the 
contribution of individual SNPs – such as the best-
described -1082 SNP – may be much less than this. 
However, at this stage the precise role of IL-10 promoter 
polymorphisms – both individually and as part of defined 
haplotypes and mosaics – in determining IL-10 
transcription and expression levels is still a subject under 
active investigation (Howell and Rose-Zerilli, 2007). 
Multiple studies have investigated the association between 
IL-10 expression and incidence of PCa (Wang et al., 2009 
;Kesarwani et al., 2009; McCarron et al., 2002). 
Polymorphisms of the IL-10 promoter at -1082 (Eskdale  
and Gallagher, 1995 ;Crawley et al., 1999), and  -592 
(Faupel-Badger et al., 2008) reduce protein expression, 
and associate with an increased incidence of PCa in some 
reports (McCarron et al., 2002; Eskdale  and Gallagher, 
1995 ;Crawley et al., 1999 ;Faupel-Badger et al., 2008). In 
contrast, genetic variation at -592, or -1082 or the promoter 
haplotype ATA resulted in no association in others (Eder et 
al., 2007 ; Michaud et al., 2006). These discrepancies 
suggest that further investigation of the association of IL-10 
SNPs with PCa is acceptable. Additionally, no such studies 
have analyzed the impact of these polymorphisms on PCa 
risk in north Indian patients. Therefore, the present study 
aims in analyzing the association of IL-10 592 C/A, IL- 10 
1082G/A polymorphisms with prostate cancer risk in north 
Indian population. 
 
 
MATERIALS AND METHOD 
 
Characteristics of study subjects  
 
This study included 150 diagnosed prostate cancer cases 
recruited from the hospitals of post graduate institute of 
medical education and research, Chandigarh, all Indian 
Institute of Medical research, New Delhi and Government 
medical college hospital, Patiala, north India. 150 benign 
prostate hyperplasia age matched subjects and 150 health 
control groups from the same geographical area were also 
participated in this case control  study.   All  healthy  control  
 
 
 
 
patients underwent screening and had a normal serum 
prostate-specific antigen (PSA) level (< 4 ng/mL).  
Genotyping of Ll-10-592 C/A and IL-101080G/A 
Blood samples of study subjects were collected in EDTA 
coated vacutinous tubes.  Genomic DNA was extracted 
from epithelial buccal cells with sequential 
phenol/chloroform solution and precipitated with 
salt/ethanol solution (Scarel-Caminaga et al., 2004). 
Genotyping of the promoter region of IL-10 -592C/A 
polymorphisms were amplified using the following primers:  
forward 5’-CCTAGGTCACAGTGACGTAA-3’, reverse 5’- 
GGTGAGCACTACCTGACTAGC-3’. PCR reaction was 
performed in a total volume of 25µl reaction mixture 
containing 100ng of genomic DNA, 10X KCl buffer, 1.5mM 
MgCl2 , 0.2mM of each dNTP, 25 pm of each primer, 1 U 
Taq polymerase and 19µl of distilled water. 
 
The PCR 
condition was denaturation at 95
0
C for 5 min. followed by 
30 cycles of 95
0
C for 45 seconds, 58
0
C for 45 seconds, 
72
0
C for 1 min. for denaturation, annealing and extension, 
respectively and final extension at  72
0
C for 7 min.  RFLP 
reaction was carried out in 15µl reaction mixture containing 
10µl of 412bp PCR product (Fig. 1), 1.8µl of buffer, 2 U of 
RSa I enzyme and 3µl of distilled water. The reaction 
mixture was incubated at 37
 o
C for 16 hours. The digestion 
with Rsa I site yielded 236 and 176bp products. The 
undigested 412bp product revealed AA and the digested 
fragment CC genotype. The heterozygous AC genotype 
was identified by the presence of 412, 236 and 176 bp 
products (Fig. 2) 
The promoter region of IL 10- 1082 single nucleotide 
polymorphism (PCR-ARMS (amplified resonance mutation 
system)) was amplified with primers following the 
techniques of Langsenlehne et al. (2005) that generated 
313 pb PCR product (Langsenlehner et al., 2005). The 
primer sequences are Forward 5’-
TTTCCAGATATCTGAAGAAGTCCTG-3’, Reverse 5’-
GTAAGTTTCTGTGGCTGTAGTC-3’,the G alleles 5’-
AACACTAAGGCTTCTTTGGGTG-3’ and the A allele with 
5’-AACACTAAGGCTTCTTTGGGTA-3’. Similar PCR 
reaction mixture like the IL-592C/A was utilized in the 
amplification of IL-1080G/A polymorphism. The PCR 
condition for this gene was employed as follows. 
Denaturation at 95
0
C for 5 min. followed by 30 cycles of 
95
0
C, 65
0
C, 72
0
C for 30 seconds and final extension of 72 
0
C for 5 min.  
Statistical analysis  
Chi-square analysis was utilized to test the frequencies 
of the genotype and alleles. Age,, occupation, smoking and 
drinking status were tabulated for cases and control 
groups. The association between polymorphism of IL-10 -
592 A/C, IL-10-1082 G/A  polymorphism with the risk of 
prostate cancer was estimated by computing odds ratio 
(OR) and 95% confidence intervals (95% CI), using a 
multivariate logistic regression analysis that included 
several variables such as age, smoking, drinking, 
occupation,  family  history  and  stage  of the disease. The  
 
 
 
 
 
 
Figure 1. PCR amplified agarose gel picture of IL-10-592 
Lane 1 412 bp pcr product 
Lane 8 100 bp DNA markes 
 
 
 
 
Figure 2.  PCR RFLP (Rsa I) digest agarose gel reperesentative picture of IL-10-592 
Lanes 1 and 4 236 and 176 bp CC genotype 
Lanes 2 and 5 412, 236 and 176 bp AC genotype 
Lane 3 412 bp AA genotype 
Lane 6 100 bp DNA marker 
 
 
 
 
Figure 1. ARMS agarose gel representative figure of IL-10- 1082 
Lanes 1 and 11 100 bp DNA ladder 
(upper band 313 bp internal control) 
Lanes 2 and 3 161 bp GG 
Lanes 4 and 5 161 bp AA 
Lanes 6, 7 161 bp GA 
  
 
 
 
 
                   Table 1. IL-10 -592 A-C   genotype frequencies, OR and 95% CI for prostate cancer among cases and controls 
 
Genotype  Cases Conterols  OR (95% CI) 
AA 63 (42.0%) 75 (50 %) 1.0 Ref. 
AC 75 (50%) 67 (44.7%) 1.33 (0.81-2.19) 
CC 12 (8%) 8(5.3%) 1.79 (0.63-5.15) 
Allelic frequency  
201 
 
217 
 
1.0 Ref.  A 
C 99 83 1.29 (0.89-1.85) 
 
                   OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (centre for disease control and prevention ). 
 
                   Table 2. IL-10 -592 A-C   genotype frequencies and OR and 95% CI for prostate cancer among cases and BPH 
 
Genotype  Cases BPH OR (95% CI) 
AA 63 (42.0%) 71 (47.3%) 1.0 Ref. 
AC 75 (50%) 69 (46.0%) 1.22 (0.74-2.02) 
CC 12 (8%) 10 (6.7%) 1.35 (0.50-3.66) 
Allelic frequency  
201 
 
211 
 
1.0 Ref.  A 
C 99 89 1.17 (0.81-1.67) 
 
                  OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (centre for disease control and prevention ). 
 
 
Table 3. Genotype distribution of IL-10 -592 A/C polymorphism in comparison with smoking among prostate cancer patients and controls.  
 
 
Genotype  
       Smokers   
OR (95% CI) 
       Non smokers    
 OR (95% CI) cases controls cases controls 
AA 24 (16%) 22 (14.7%) 1.23 (0.85-1.77) 39(ref.)  (26%) 53(ref.)  (35.3%) 1.0 
AC 20 (13.3%) 15 (10%) 1.81 (0.77-4.29) 55 (36.7%) 52 (34.7%) 0.85 (0.39-1.82) 
CC 4 (2.7) 3 (2%) 1.35 (0.68-2.67) 8 (5.3%) 5 (3.3%) 1.43 (0.64-3.18) 
 
OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (centre for disease control and prevention) 
 
         Table 4. Genotype distribution of IL-10 -592 A/C polymorphism in comparison with smoking among prostate cancer patients and BPH. 
 
 
Genotype  
       Smokers   
OR (95% CI) 
       Non smokers    
 OR (95% CI) cases BPH cases BPH 
AA 24 (16%) 16 (10.7%) 1.16 (0.79-1.68) 39 ((ref.) 26%) 55 (ref.) (36.7%) 1.0 
AC 20 (13.3%) 18 (12%) 1.57 (0.69-3.58) 55 (36.7%) 51(34%) 0.87 (0.40-1.86) 
CC 4 (2.6) 2 (1.3%) 1.61 (0.87-2.99) 8 (5.3%) 8 (5.3%) 1.07 (0.45-2.54) 
 
         OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (centre for disease control and prevention) 
 
 
statistical analysis was performed using Epi-Info software 
(Epi-Info, version 3.5.1). 
Written informed consent was obtained from all cases 
and controls. The study was carried out after obtaining 
approval from the Ethics Committee of the Postgraduate 
Institute of Medical Education and Research, Chandigarh, 
India. 
 
 
RESULTS 
 
Demographic characteristics of study subjects  
 
The mean age among cases, controls and BPH study 
subjects was 67.49±7.92, 65.57± 8.21 and  66.71±9.24, 
respectively. p value was greater than 0.05 for both cases, 
BPH and healthy controls. Among cases 56.7% were from 
rural and the remaining 43.3% were from urban area. In 
the BPH study subjects 56% were from urban as compared 
to the remaining 44% from rural area. On the other hand, 
57.3% of controls were from rural as opposed to 42.7% 
from urban area. Regarding occupation 46% of cases were 
sedentary workers, 50.7% were manual and the rest 3.3 % 
were industrial workers. In BPH, study subjects sedentary 
workers were 45.3%, manual 52% and 2.7% were 
industrial workers. When the percentage of occupation 
among controls was analyzed sedentary, manual and 
industrial workers were 48, 49.3 and 2.7%, respectively. 
Regarding smoking status there were 102 (68%) non 
smokers   within  cases,  114 (76%)  BPH and 110 (73.3%)  
 
 
 
 
              Table 5. IL-10 1082 A-G  genotype frequencies and OR and 95% CI for prostate cancer among cases and controls  
  
Genotype  Cases Controls OR (95% CI) 
AA 50 (33.3%) 47 (31.3%) 1.0 
AG 73 (48.0%) 75 (50.0%) 0.91 (0.53-1.58) 
GG 27 (18.0%) 28 (18.7%) 0.91 (0.44-1.85) 
Allelic frequency  
173 
 
169 
 
1.0 A 
G 127 131 0.95 (0.68-1.33) 
 
               OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (centre for disease control and prevention) 
 
                 Table 6. IL-10 1082 A-G  genotype frequencies and OR and 95% CI for prostate cancer among  cases and BPH 
 
Genotype  Cases BPH OR (95% CI) 
AA 50 (33.3%) 45 (30%) 1.0 Ref. 
AG 73 (48.0%) 79 (52.7) 0.83 (0.48-1.44) 
GG 27 (18.0%) 26 (17.3%) 0.93 (0.70-1.34) 
Allelic frequency                                                    
A 173 169 1.0 Ref. 
G 127 131 0.95 (0.68-1.33) 
 
                  OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (center for disease control and prevention ). 
 
  
 
           Table 7. Genotype distribution of  IL-10 -1082 A-G  polymorphism in comparison with smoking among prostate cancer patients and controls. 
 
 
Genotype  
       Smokers   
OR (95% CI) 
       Non smokers    
 OR (95% CI) cases controls cases controls 
AA 15 (10%) 13 (8.7%) 1.12 (0.43-2.96) 35 (ref.) (23.3%) 34 (ref.) (22.7%) 1.0 Ref. 
AG 26 (17.3%) 19 (12.6) 1.33 (0.58-3.04) 47 (31.4%) 56 (37.4) 1.05 (0.46-2.43) 
GG 7 (4.6%) 8 (5.3%) 0.85 (0.24-2.96) 20 (13.4) 20 (13.4) 0.79 (0.24-2.55) 
 
          OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (center for disease control and prevention) 
  
 
                    Table 8. Odds ratio (OR) and corresponding 95% confidence interval (CI) for the combined effect of IL-10- 592 A-C and  IL-10 1082 A-G 
 
IL-10 -592 IL-10 1080 Cases (%) Control (%) BPH (%) OR (95%CI) 
AA AA 21 (14) 27 (18) 25 (16.7) 1.0 Ref. 
AG 29 (19.3) 38 (25.3) 29 (19.3) 0.98 (0.43-2.22) 
GG 13 (8.7) 10 (6.7) 17 (11.3) 1.67 (0.55-5.14) 
 
AC  
AA 23 (15.3) 17 (11.3) 18 (12) 1.74 (0.69-4.44) 
AG 40 (26.7) 34 (22.7) 42 (28) 1.51 (0.68-3.36) 
GG 12 (8) 16 (10.7) 9 (6) 0.96 (0.34-2.74) 
 
CC 
AA 6 (4) 3 (2) 2 (1.3) 1.52 (0.87-2.67) 
AG 4 (2.7) 3 (2) 8 (5.3) 1.31 (0.64-2.68) 
GG 2 (1.3) 2 (1.3) - 1.14 (0.41-3.20) 
 
 
 
within controls. The remaining 32% in cases, 24% in BPH 
and 26 % in controls were smokers. Whenever the status 
of alcoholism was analyzed 58.7% of cases were non 
drunker as compared to 59.3% in controls and 58% in 
BPH. The rest 41.3% had reported drinking at least 3 times 
per week in cases and 40.7% and 41.3% had reported 
having similar drinking situation in controls and BPH, 
respectively.  
Table 1 demonstrates the frequencies of the three 
genotypes of IL-10-592 A-C polymorphism among cases 
and healthy controls. The percentages of AA, AC and CC 
genotypes among cases were 42, 50 and 8, respectively. 
However, in BPH the percentage of AA genotype was 47.3  
and while that of AC and CC were 46 and 6.7, respectively. 
Statistically non significant 1.29 folds of marginal increased 
risk to prostate cancer among cases was associated with  
 
 
 
 
the CC genotype of IL-10 -592 A-C gene (OR=1.29, 
95%CI=0.89-1.85).  
Table 2 describes the frequencies of the three genotypes 
of IL-10-592 A/C polymorphism among cases and BPH. 
The percentages of AA, AC and CC genotypes among 
cases were 42, 50 and 8, respectively. However, in BPH 
the percentage of AA genotype was 47.3 and while that of  
AC and CC were 46 and 6.7, respectively. Statistically non 
cancer among cases was associated with the CC genotype  
of IL-10 -592 A-C gene (OR=1.35, 95%CI=0.50-3.66). 
significant 1.35 folds of marginal increased risk to prostate 
The relative risk of smoking in association with IL-10-592 
A/C polymorphism among cases and controls is given in 
Table 3. The percentages of the three genotypes of IL-10 -
592 A/C polymorphism in smoker cases were AA 16, AC 
13.3 and CC 2.7, respectively. The percentages of the 
three genotypes in smoker controls were 14.7, 10 and 2 for 
AA, AC and CC genotypes, respectively. The association 
of smoking and IL-10- 592 A/C genotype of cases was 
computed against healthy non smoking controls. There 
was statistically non significant 1.81 folds of increased risk 
of prostate cancer to cases due to the  association of 
smoking and AC genotype of IL-10 -592 A/C genotype 
(OR=1.81, 95% CI=0.77-4.29).  
The relative risk of prostate cancer in smoker cases 
along with IL-10-592 C/A polymorphism was computed 
against BPH non smoking study subjects in Table 4. The 
frequency of the three genotypes in smoker BPH study 
subjects were 10.7, 12, and 1 percent for AA, AC and CC, 
respectively. There was no statistically significant variation 
among cases and BPH when ever smoking was taken as a 
risk factor along with IL- 10-592 polymorphic forms. 
However, statistically non significant increased risk of 
prostate cancer was associated with AC and CC 
genotypes of IL-10-592 polymorphism in cases (OR= 
1.57,95% CI= 0.69-3.58 and 1.67, 95 % CI 0.87-2.99, 
respectively). 
Whenever the effect of alcohol along with polymorphism 
of IL-10-592 A/C towards overall risk of prostate cancer is 
computed, there were 19.3% AA genotype carriers from all 
alcoholic cases and the percentage of AC genotype in 
drunker cases was 18, the remaining 4% drunker had the 
CC genotype. On the hand, there were 22% AA genotype 
carriers among drunken controls and the percentage of AC 
and CC genotype within drunker controls were 16.7 and 2, 
respectively. The association of alcohol to the risk of 
prostate cancer in cases was computed against non 
alcoholic healthy controls. There was statistically non 
significant association of alcohol and alcohol and CC 
genotype of IL-10-592 in cases (OR= 1.49, 95 %CI= 0.88-
2.52). 
The percentage of the three genotypes of IL-10 1080 
A/G  genotype  is  given  in  Table  5.  The frequency of AA  
genotype in cases was 33.3 percent and it was 31.3 
percent in controls. The frequency of the heterozygous AG 
genotype in cases was 48 percent and it was 50 percent in  
 
 
 
 
controls. The percentage of the homozygous GG genotype 
was 18 percent in cases and it was 18.7 percent in 
controls. No statistically significant difference in the 
genotype frequency among cases and control was 
observed.  
The frequency of IL-10 1082 A/G genotype 
polymorphism in cases was also computed against BPH 
study subjects (Table 6). The percentages of the three 
genotypes   in  BPH  were  AA 30,  AG 52.7  and  GG 17.3, 
respectively. When risk of prostate cancer in cases was 
analyzed against BPH study subjects, there was 
statistically non significant association for risk of prostate 
cancer among cases in regard to this gene polymorphism. 
The effect of smoking, Il-10 1082 A/G polymorphism and 
the risk of prostate cancer is computed in Table 7. The 
percentage of AA, AG and GG genotypes in smoker cases 
were 10, 17.3 and 4.6, respectively. The percentages of 
the three genotypes in non smoker cases were 23.3, 31.4 
and 13.4. The percentages of AA, AG and GG genotypes 
in smoker controls were 8.7, 12.6 and 5.3, respectively. 
The OR for smoking and this gene polymorphism for cases 
were computed against healthy non smoker controls. 
There was no statistically significant association between 
smoking, this gene polymorphism and risk of prostate 
cancer.  
The gene-gene interaction of IL-10-592 A/C and IL-10-
1082 A/ G is given in Table 8. There was statistically no 
significant association between any of these genotype 
combinations and risk of prostate cancer in cases. 
However, statistically non significant 1.74 and 1.67 folds of 
increased risk of prostate cancer was observed due to the 
gene-gene interactions of AC of IL-10-592, d GG of IL-10 
1082 and AA of IL-10 -592,  CC of IL-10 1082,  
respectively.  
 
 
DISCUSSIONS  
 
Interleukin (IL-10) is considered as a key mediator of 
immunosuppressant and tolerance. It appears to be 
primarily produced by monocytes and T regulatory (Tr)1-
lymphocytes and to act on a number of cells, including 
monocytes, helper and cytotoxic T cells as well as B cells. 
IL-10 was shown to play a role in a broad variety of tumors, 
autoimmune and infectious diseases (Moore et al., 2001). 
Evidence for its immunosuppressive activity has been 
based on the observations that (i) increased production of 
IL-10 in vivo and in animal models was associated with 
states of Immunosuppression (Mahanty et al., 1996; 
Plebanski et al., 1999) (ii) neutralizing antibodies to IL- 10 
reversed hyporesponsiveness of T cells in vivo, (King et 
al., 1993 ; Osborne and Devaney 1999) and (iii) deletion of 
the IL-10 gene  rendered  mice  more resistant to tumors or  
infection and more susceptible to infection pathology or 
autoimmune disease (Kuhn et al., 1993; Hoffmann et al., 
2001). 
 
 
 
 
The promoter polymorphisms of IL-10 have been subject to 
the most scrutiny, particularly with regard to possible 
influences upon gene transcription and protein production. 
For example, the IL-10 -1082 SNP and -1082, -819, -592 
haplotype have been reported to be associated with 
differential IL-10 expression in vitro, with the -1082 A, -819 
T,-592 A haplotype associated with decreased IL-10 
expression, compared with the -1082 G, -819 C, -592 C 
haplotype  (Howell  and  Rose-Zerilli,  2006).  It  has   been 
proposed that IL-10 might contribute to the tumorigenesis 
of various types of cancers such as lymphoma (Levy and 
Brouet, 1994) colon (Gastl et al., 1993), and ovarian (Pisa 
et al., 1992). Moreover, Kozlowski and co-workers (2003) 
reported higher amount of IL-10 in breast cancer patients 
compared to healthy women, and also a correlation 
between IL-10 levels and clinical stages of the disease 
(Kozlowski et al., 2003). However, anti-tumor effects of IL-
10 via mechanisms such as inhibition of angiogenesis and 
enhancing anti-tumor activity of natural killer cells have 
also been described (Kundu and Fulton 1997; Sturlan et 
al., 2001). 
In the present study IL-10-592 A/C and Il-101082 A/G 
polymorphisms were analyzed to see its role in risk of 
prostate cancer in north Indian study subjects. No 
statistically significant association for risk of prostate 
cancer was observed to any of the genotypes of IL-10-592 
polymorphism. However, statistically non significant slight 
increased risk of prostate cancer was associated between 
the CC genotype of cases (OR= OR=1.79, 95% CI=0.63-
5.15).  This non significant association could be explained 
in that, IL10 –592CC genotype has been related to a low 
IL-10 production capacity (Temple et al., 2003) trough this 
balance between pro and anti inflammatory situation may 
interplay leading in to more inflamination and occurrence of  
cancer. Our result is consistent with four studies that 
examined variation in IL-10 loci and association with 
prostate cancer incidence and/or tumor characteristics. 
Three of these studies found no association. Eder and 
colleagues (2007) examined the -592 IL-10 SNP and found 
no association with the development of prostate cancer 
(Sturlan et al., 2001). Xu et al. (2005) also did not find an 
association between the IL-10 SNPs at -1082 and -592 and 
prostate cancer incidence (Eder et al., 2007). Similar to our 
study the study by Eder et al. (2007) and Xu et al. (2005) 
showed the minor allele frequencies at these loci did not 
differ between cases and controls (Sturlan et al., 2001 
;Eder et al., 2007). Moreover, Michaud and colleagues 
(2006) examined genetic variation in three IL-10 loci in 
subjects from the United States participating in the 
Prostate, Lung, Colorectal, and Ovarian Cancer Screening 
Trial and did not find an association of genotype at any of 
the   loci   with prostate   Cancer (Xu et al., 2005). 
However,    Faupel- Badger  et al.   (2008)   reported   that  
homozygous variant alleles at either -819 or -592 in the IL-
10 promoter are associated with increased risk of prostate 
cancer among American population (Michaud et al., 2006).  
 
 
 
 
The difference between our results and this report may be 
due to sampling or to inherited genetic differences between 
these two populations. Moreover, Faupel- Badger and 
colleagues have examined three polymorphic loci at the 
promoter region of IL-10, however, in this study only two 
loci has been studied due to unavailable circumstances. 
While a large number of investigations of possible 
associations between IL-10 genotypes and immune 
mediated  disease have been performed, the literature with 
regard to IL-10 polymorphisms and cancer is as yet small, 
but growing (Michaud et al., 2006). 
Whenever risk factors like smoking and alcoholism were 
computed we did not find significant association with risk of 
prostate cancer in cases this may be most likely due to 
less power of the statistics as number of smokers and 
alcoholic cases reported in this study were very small.  
Interleukin-10 (IL-10) is an anti-inflammatory cytokine, 
which is involved in down- regulating cell-mediated and 
cytotoxic inflammatory responses (Faupel-Badger et al., 
2008). IL-10 polymorphism has been extensively studied 
and reported to be associated with other cancers and 
diseases. A case-control study including 500 female 
patients with histological confirmed breast cancer and 500 
female, age matched, healthy control subjects conducted 
by Langsenlehner and colleagues suggested that IL-10 
promoter polymorphism was associated with decreased 
breast cancer risk (Zhou et al., 2008). A prospective, case-
control study including 147 patients with advanced ovarian 
cancer conducted by Ioana and colleagues showed that IL-
10 promoter polymorphism may be related with the ability 
to achieve optimal tumour debulking, and it seemed to 
influence the overall and disease-free survival rate 
(Langsenlehner et al., 2005).  In this study, where 
polymorphisms of IL-10-1082 G-A was analyzed to see its 
effect as risk factor for PCa, there was no statistically 
significant association  for risk of PCa and this gene 
polymorphism in north Indian population.  
IL-10-G1082A polymorphism is correlated with the 
expression of IL-10 and accordingly affects the 
susceptibility to some types of tumors, such as cervical 
cancer (Ioana Braicu et al., 2007) and prostate cancer 
(Roh et al., 2002). Although the expression of IL-10 gene 
might be associated with the susceptibility to esophageal 
scoumous cell carcinoma (McCarron et al., 2002), the 
correlation of IL-10 -1082 promoter polymorphism with the 
risk of prostate cancer  in north Indian population  has not 
been reported so far. Some workers have suggested that 
as much as 75% of inter-individual variation in IL-10 
expression may be due to genetic variation, although 
others believe that the contribution of individual SNPs – 
such as the best-described -1082 SNP – may be much 
less than this. However, at this stage the precise role of IL-
10 promoter polymorphisms – both individually and as part  
of defined haplotypes and mosaics  in determining IL-10 
transcription and expression levels is still a subject under 
active investigation (Howell and Rose-Zerilli, 2006).  
 
 
 
 
Whenever life style risks like smoking and alcoholism were 
analyzed to determine their role in prostate cancer risk, no 
statistically significant association was observed between 
these factors and prostate cancer. Another study with large 
sample size with same and different ethnic backgrounds is 
warranted to exactly determine the association between 
this polymorphism, lifestyle and risk of prostate cancer.  
While the precise mechanisms by which IL-10 
polymorphisms  may  modulate  PCa  progression remains 
known, evidence suggests that IL-10 modulates immune 
function, such as NK cell, T cells, and macrophages 
activity, which would alter disease progression. 
Additionally, increasing evidence suggests a role for IL-10 
inhibition of angiogenesis, therefore decreases IL-10 
expression would depress angiogenic activity and promote 
cancer progression (Nagata et al., 2002). The non 
significant association of increased PCa risk duo to the 
gene- gene interaction of AC of IL-10-592 and GG of IL-10 
1082  indicated in this study might be due to the genotypic 
interplay of the two genes which may decrease the 
secretion of IL-10 that enhances inflaminaion through 
indirect role. However, this needs to be confirmed in virto 
and in vivo studies and thus, other similar studies in the 
same and different population with increase sample size is 
recommended.  
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